Lv5
1110 积分 2024-08-16 加入
ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer
5天前
已关闭
Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
8天前
已完结
Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
9天前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1个月前
已完结
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition
1个月前
已完结
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
2个月前
已完结
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
2个月前
已完结
Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis
2个月前
已完结
CAR T-cell therapies in China: rapid evolution and a bright future
2个月前
已完结
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
2个月前
已完结
皖公网安备34019202002308
